Home
Trade
SpotFuturesStocks
LendBP
Tools
WatchlistsScreenerGraphsCalendar

More

​$​0123456789​.01234567890123456789​

Today

$0.00

+0.00%

Mkt Cap

Volume

Next Earnings

ChartFinancialsNewsAbout
Kyverna Therapeutics, Inc. Common Stock

Kyverna Therapeutics, Inc. Common Stock

Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product, KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.

kyvernatx.com

Ticker

KYTX

Market cap

$522.23M

IPO Date

Feb 8, 2024

Employees

149

Balances
Positions
Open Orders
Borrows
TWAP
Fill History
Order History
Position History
Funding History
All
Crypto
Stocks
Asset

Brokerage services in your region are provided through Trek Brokerage Services Limited, a company licensed by the Anjouan Offshore Finance Authority, acting as Intermediary Broker pursuant to the Backpack Securities Brokerage Services Terms of Service. Please see our Brokerage Services Terms and Conditions available here. Investing in stocks involves risks, including the total loss of your investment. The value of investments can go down as well as up, and past performance is not a reliable indicator of future results. You should consider seeking independent financial or legal advice before making any investment decision. It is your responsibility to ensure that your use of this platform and any investments made comply with the laws and regulations of your jurisdiction.